MARKET

TPTX

TPTX

Turning Point Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

68.25
-1.00
-1.44%
Closed 16:00 06/01 EDT
OPEN
69.37
PREV CLOSE
69.25
HIGH
69.90
LOW
62.43
VOLUME
279.88K
TURNOVER
--
52 WEEK HIGH
69.90
52 WEEK LOW
31.30
MARKET CAP
2.45B
P/E (TTM)
-19.5828
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TPTX stock price target is 76.88 with a high estimate of 88.00 and a low estimate of 65.00.

EPS

TPTX News

More
The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 1)
Benzinga · 22m ago
Stocks That Hit 52-Week Highs On Monday
On Monday, 78 companies set new 52-week highs.
Benzinga · 21h ago
Turning Point Therapeutics to Participate in Goldman Sachs 41st Annual Global Healthcare Conference Webcast
GlobeNewswire · 22h ago
Informative Insider Purchasing Activity - Weekly Update (05/22/20-05/29/20)
Seeking Alpha - Article · 2d ago
Turning Point Therapeutics Presents Preclinical Data For Novel RET Inhibitor Candidate, TPX-0046
GlobeNewswire · 3d ago
The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 28)
Benzinga · 4d ago
Trade Alert: The President Of Turning Point Therapeutics, Inc. (NASDAQ:TPTX), Athena Countouriotis, Has Just Spent US$250k Buying 18% More Shares
Simply Wall St. · 4d ago
Turning Point Therapeutics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Common Stock
Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that the underwriters of its previously announced underwritten public offering of its common stock
GlobeNewswire · 5d ago

Industry

Biotechnology & Medical Research
+0.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About TPTX

Turning Point Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies. Its tyrosine kinase inhibitors (TKIs) pipeline targets numerous genetic drivers of cancer in both TKI-naive and TKI-pretreated patients. The Company has developed a macrocycle platform enabling to design proprietary small, compact TKIs with rigid three-dimensional structures that potentially bind to their targets with greater precision and affinity than other kinase inhibitors. The Company’s lead drug candidate, repotrectinib (TPX-0005), is being evaluated in an ongoing Phase I/II trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors.
More

Webull offers kinds of Turning Point Therapeutics Inc stock information, including NASDAQ:TPTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TPTX stock news, and many more online research tools to help you make informed decisions.